LENZ Therapeutics’ (LENZ) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of LENZ Therapeutics (NASDAQ:LENZ) in a research note released on Thursday,Benzinga reports. They currently have a $38.00 price target on the stock.

Several other brokerages have also commented on LENZ. Raymond James started coverage on shares of LENZ Therapeutics in a research note on Friday, September 27th. They set an “outperform” rating and a $37.00 price target on the stock. William Blair upgraded LENZ Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Finally, Piper Sandler reissued an “overweight” rating and issued a $36.00 target price on shares of LENZ Therapeutics in a research report on Thursday, August 15th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, LENZ Therapeutics has a consensus rating of “Buy” and an average target price of $35.40.

LENZ Therapeutics Trading Up 7.8 %

LENZ opened at $35.07 on Thursday. LENZ Therapeutics has a one year low of $14.07 and a one year high of $37.13. The business’s 50-day simple moving average is $24.94 and its 200-day simple moving average is $21.27.

LENZ Therapeutics (NASDAQ:LENZ) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.09. During the same quarter in the previous year, the business earned ($1.33) earnings per share. On average, analysts expect that LENZ Therapeutics will post -3.15 earnings per share for the current year.

Institutional Investors Weigh In On LENZ Therapeutics

Several hedge funds have recently made changes to their positions in LENZ. GSA Capital Partners LLP acquired a new position in LENZ Therapeutics in the 3rd quarter valued at about $246,000. SG Americas Securities LLC purchased a new position in shares of LENZ Therapeutics in the 3rd quarter valued at approximately $107,000. Deerfield Management Company L.P. Series C acquired a new position in shares of LENZ Therapeutics in the second quarter valued at approximately $300,000. Squarepoint Ops LLC acquired a new position in shares of LENZ Therapeutics in the second quarter valued at approximately $181,000. Finally, Marshall Wace LLP purchased a new stake in shares of LENZ Therapeutics during the second quarter worth approximately $390,000. Institutional investors and hedge funds own 54.32% of the company’s stock.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.